Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
Dual Thrombolytic Therapy With Mutant Pro-urokinase and Low Dose Alteplase for Ischemic Stroke

Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by IV infusion of mutant pro-urokinase against usual treatment with IV alteplase in patients presenting with ischemic stroke.

urokinase
thrombolytic drugs
stroke
intracranial hemorrhage
alteplase
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study to Determine the Safety of AV-1 an Antibody Being Developed for Treatment of Dengue in Healthy Volunteers

This study aims to determine the safety of AV-1 in healthy adult volunteers, when administered as a single IV infusion.

12 lead ECG
12 lead electrocardiogram
electrocardiogram
tubal ligation
oophorectomy
  • 0 views
  • 16 Feb, 2024
  • 1 location
At-Risk for Type 1 Diabetes Extension Study

This study is an extension of the NIH-sponsored AT-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who develop clinical type 1 diabetes after the conclusion of that trial, are eligible to enroll and receive teplizumab treatment within one year of diagnosis of …

type 1 diabetes mellitus
teplizumab
diabetes
  • 0 views
  • 16 Feb, 2024
  • 5 locations
Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia

To evaluate the safety and efficacy of humanized Meplazumab for Injection in patients infected by 2019-nCoA.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study of 3 cohorts will be included.

metastasis
growth factor
non-small cell lung cancer
small cell lung cancer
EGFR
  • 0 views
  • 16 Feb, 2024
  • 1 location
Nivolumab Ipilimumab and Chemoradiation in Treating Patients With Locally Advanced Pancreatic Cancer.

Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy. A locally unresectable tumor (locally advanced pancreatic cancer (LAPC)) is present in 30% of the cases and is defined as a surgically unresectable tumor encasing the adjacent arteries [celiac …

chemotherapy regimen
cancer chemotherapy
gilbert's syndrome
paclitaxel
teratogenicity
  • 0 views
  • 16 Feb, 2024
  • 1 location
Cyclosporine in Patients With Moderate COVID-19

Phase 1 safety study to determine the tolerability, clinical effects, and changes in laboratory parameters of short course oral or IV cyclosporine (CSA) administration in patients with COVID-19 disease requiring oxygen supplementation but not requiring ventilator support.

oxygen supplementation
cyclosporine
SARS
cyclosporin a
acute respiratory syndrome (sars)
  • 0 views
  • 16 Feb, 2024
  • 1 location
Immunity and Safety of Covid-19 Synthetic Minigene Vaccine

In December 2019, viral pneumonia caused by a novel beta-coronavirus (Covid-19) broke out in Wuhan, China. Some patients rapidly progressed and suffered severe acute respiratory failure and died, making it imperative to develop a safe and effective vaccine to treat and prevent severe Covid-19 pneumonia. Based on detailed analysis of …

  • 0 views
  • 16 Feb, 2024
  • 3 locations
Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes (KIBOU-T1D)

This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment.Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage …

  • 0 views
  • 25 Jul, 2025
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Around 100 participants will be enrolled in the study in approximately 44 sites across United States. Participants will receive intravenous (IV) infusion of pembrolizumab alone or in combination with oral venetoclax tablets. There will be higher treatment burden for participants in this trial compared to their standard of care.

pembrolizumab
growth factor
non-small cell lung cancer
blood test
epidermal growth factor
  • 0 views
  • 16 Feb, 2024
  • 39 locations